Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway

Blanka Nechanská1, Viktor Mravčík1,2, Svetlana Skurtveit3,4, Ingunn Olea Lund3,4, Roman Gabrhelík1, Anders Engeland3,5 & Marte Handal3

Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 1 National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic, 2 Norwegian Institute of Public Health, Oslo, Norway, 3 Norwegian Centre for Addiction Research at the University of Oslo, Oslo, Norway, 4 and Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

ABSTRACT

Background and Aims Opioid maintenance treatment (OMT) is recommended to opioid-dependent females during pregnancy. However, it is not clear which medication should be preferred. We aimed to compare neonatal outcomes after prenatal exposure to methadone (M) and buprenorphine (B) in two European countries. Design Nation-wide register-based cohort study using personalized IDs assigned to all citizens for data linkage. Setting The Czech Republic (2000–14) and Norway (2004–13). Participant Opioid-dependent pregnant Czech (n = 333) and Norwegian (n = 235) women in OMT who received either B or M during pregnancy and their newborns. Measurements We linked data from health registries to identify the neonatal outcomes: gestational age, preterm birth, birth weight, length and head circumference, small for gestational age, miscarriages and stillbirth, neonatal abstinence syndrome (NAS) and Apgar score. We performed multivariate linear regression and binary logistic regression to explore the associations between M and B exposure and outcomes. Findings Most neonatal outcomes were more favourable after exposure to B compared with M, but none of the differences was statistically significant. Conclusions Two national cohorts of women receiving opioid maintenance treatment during pregnancy showed small but not statistically significant differences in neonatal outcomes in favour of buprenorphine compared with methadone.

Keywords Buprenorphine, health registries, methadone, neonatal outcomes, opioid maintenance treatment, prenatal exposure.

INTRODUCTION

Pregnant women with opioid dependence, according to the World Health Organization (WHO) guidelines for identification and management of substance use and substance use disorders in pregnancy, should be advised to continue or commence pharmacotherapy with either methadone or buprenorphine [1,2]. Such pharmacotherapy combined with psychosocial support is often called opioid maintenance treatment (OMT). However, while WHO strongly recommends OMT during pregnancy, the same guidelines underscore that the quality of the evidence behind this recommendation is, to date, very low. The most used medications for OMT are methadone (M), and buprenorphine (B), alone or in combination with naloxone (BN). M and B are both long-acting opioid agonists, but differ somewhat with respect to pharmacological properties [3]. While the WHO guidelines recommend M for pregnant opioid-dependent women, national recommendations for this patient group might
differ, and in some countries B is recommended as the OMT drug of choice [4,5]. In the United States, both M and B are considered as treatment options for pregnant women [6].

The first studies, in the 1970s, compared neonatal outcomes of children born to opioid-dependent women who received M treatment to that of children born to pregnant women using heroin [7–9]. Except for more severe neonatal abstinence syndrome (NAS), children exposed to M had better neonatal outcomes than children exposed to heroin but worse than children born to mothers in the general population [7]. B was approved as an OMT drug in 2000 in some European countries. In contrast to M, which is a full agonist, B is a partial agonist [10]. Thus, B may not be as good choice as M to treat the most severely addicted patients.

Two recently published systematic reviews and meta-analyses reported that prenatal exposure to B gave more favourable neonatal outcomes compared to M exposure [11,12]. However, in one study the authors also performed simulation analysis, suggesting that confounding by indication could explain some of the more favourable effects of B, and the authors stated that more evidence is needed to guide treatment choices [11].

Most previous studies of M versus B treatment during pregnancy were based on small samples [13–17]; some were not representative of the entire population of pregnant women who receive OMT [11,12], and many were based mainly on urban populations [18]. In contrast to most countries, both the Czech Republic and Norway have nation-wide health registries that use personalized identification number for all citizens; this makes linkage of registry data on individual and family levels possible [19]. Employing registry data allows us to study large unselected populations of pregnant OMT women from countries with different socio-economic and treatment settings.

Our aim was to compare neonatal outcomes from prenatal exposure to B versus M in the Czech Republic and Norway.

**METHODS**

**Setting**

**Czech Republic**

M became available for pregnant women at one treatment facility in 1997 [20], B in 2000 and BN in 2008 [21]. OMT treatment facilities have expanded gradually, from six facilities in 2000 [22] to 63 facilities in 2015. Of these, 13 were methadone centres providing M and B/BN; the rest provide B/BN only [23].

M is provided at OMT clinics only, but B and BN are available in pharmacies and may be prescribed by any physician [24]. M is provided free of charge at clinics, while B and BN is typically paid fully by the patients.

**Norway**

OMT became available nation-wide in 1998, first with M and later with B (2000) and BN (2007) [25]. M was recommended early as the first choice but, from 2005, B has been recommended as the first-line drug. OMT is organized through regional centres under the specialist health-care service, and to receive OMT patients must be included in the national OMT programme. OMT is free of charge. For most patients contact with specialist health care is ambulatory, and most pregnant women in OMT receive their OMT medication at pharmacies [26].

Health-care providers are obliged by law to report use of illicit drugs during pregnancy [27]. Repeated use may result in the woman being detained, with or without her consent, at clinics that specialize in treating pregnant women with substance use problems [28].

**Data sources**

We provide a short description of the registries used in this study; a more detailed description is provided elsewhere [19,26].

**Czech Republic**

**National Register of Reproduction Health (NRRH).** The NRRH have several subregistries, including the mothers at childbirth registry and the registry of newborns. The first includes information about the mothers during pregnancy, such as demographic and socio-economic information, information about alcohol, tobacco and illegal drug use during pregnancy and information about delivery. The latter includes information about the neonate, such as birth parameters, congenital malformations and death [29].

**National Register of Addiction Treatment (NRAT).** The NRAT includes information concerning patients who receive opioid maintenance treatment, e.g. date of initiation and termination of treatment and type of OMT drug [30,31].

Physicians are obliged by law to report data to NRRH and NRAT.

**Norway**

**Medical Birth Registry of Norway (MBRN).** MBRN is based on compulsory notification of every birth or late abortion from physicians or midwives attending the birth. The MBRN includes information concerning all births and late abortions from the 12th gestational week and onwards, and includes information concerning pregnancy and delivery; the neonate (gestational age, birth parameters, NAS, congenital malformations); demographic and socio-economic background of mothers; and also maternal tobacco smoking during pregnancy.
**Norwegian Prescription Database (NorPD).** The NorPD includes information about all prescription drugs, including OMT drugs, dispensed at pharmacies to patients in ambulatory care. The drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification system [32]. Pharmacies are obliged by law to forward prescription data to NorPD.

**Statistics Norway (SSB).** From Statistics Norway we included information about maternal education. Educational institutions are obliged to report completed education on an individual level to SSB.

**Linkage of registry data**

Linkage of data between the registries was based on the personal identification numbers assigned to all individuals in the Czech Republic and Norway [19].

**Study population and study period**

The study population consisted of pregnant women in OMT and their children born during the study period; 2000–14 in the Czech Republic and 2004–13 in Norway.

**Exposure to OMT drugs during pregnancy**

Only M, B and BN are used as pharmacotherapy in OMT in the Czech Republic and Norway.

In the Czech Republic, data from the NRAT were used to identify which women were in OMT and, if so, which OMT drug they received.

In Norway, we used NorPD data to identify whether the women had used M (ATC code N07 BC02), B (N07 BC01) or BN (N07 BC51). Women who were dispensed OMT drugs from a pharmacy at least once during pregnancy were defined as using OMT drugs during pregnancy. More than 95% of all OMT women receive more than one prescription during pregnancy.

Some women switch from one substitution drug to another during pregnancy. There were no such cases in the Czech sample. In the Norwegian sample, women who switched between M and B (n = 1) during pregnancy were assigned into the M group; women who switched between BN and B (n = 29) were assigned into the BN group.

**Outcomes**

Neonatal outcomes were identified in the NRRH in the Czech data and in the MBRN in the Norwegian data.

Outcomes included: gestational age (based mainly on ultrasound examination or, if missing, the first day of the last menstrual period), preterm birth (< 37 weeks of gestation), anthropometric data (birth weight, length and head circumference), small for gestational age (SGA) [33], miscarriage (death of a fetus between gestational weeks 12 and 22), stillbirth (death of a fetus in gestational week 22 or later), NAS and Apgar scores < 7 at 1 and 5 minutes.

**Other variables**

We obtained information on socio-demographic variables, drug use and tobacco smoking from the NRRH in the Czech Republic and from the MBRN and Statistics Norway in Norway.

**Analysis strategy and statistics**

First, we analysed socio-demographic background and substance use during pregnancy for women who received pharmacotherapy with M, B or BN in the Czech Republic and Norway, respectively. Confidence intervals for proportions were calculated using the continuity-corrected score interval method [34].

Next, we presented neonatal outcomes, restricted to singleton births in both countries. Anthropometric data (except SGA) were restricted to term births (≥ 37 gestational weeks). Gestational age, SGA, NAS and Apgar scores were restricted to live births.

To control for relevant background characteristics, we performed linear regression for continuous dependent variables and binary logistic regression for categorical dependent variables. We adjusted for maternal age, marital status, education and tobacco smoking during pregnancy. We compared B to M, using M as the reference group. Unadjusted analyses in Norway were performed both in the total sample and in a sample restricted to the same study sample, as in the adjusted analysis.

Some of the neonatal outcomes were infrequent, and we only performed multivariate analysis of outcomes observed in more than four individuals. Statistical significance level was set to 0.05.

Statistical analyses were conducted using SPSS for Windows version 21.

**Ethics**

The study was approved by the Institutional Review Board of the General University Hospital in Prague (IRB00002705) and the Regional Committees for Medical and Health Research Ethics (REK, AE: 2012–222) and the Norwegian Data Inspectorate.

**RESULTS**

**Background characteristics of women in OMT**

A total number of 333 and 235 women used OMT drugs during pregnancy in the Czech Republic and Norway, respectively. Tables 1 and 2 illustrate background characteristics of pregnant women in OMT in the Czech Republic and Norway. In both countries, the main difference
between the M and B groups were that women who received M had lower education than women who received B during pregnancy; the proportion with primary education in the Czech Republic was 57.0 versus 40.9% and in Norway was 83.2 versus 57.6% (Tables 1). However, in Norway a larger proportion of B women were younger, single and smoked tobacco than M women, but the differences were not significant.

Neonatal outcomes

Tables 3 and 4 show the neonatal outcomes after exposure to M, B or BN in the Czech Republic and Norway, respectively. In both countries, there were approximately the same numbers of children exposed to M and B. Only 20 and 33 of the neonates were exposed to BN in the Czech Republic and Norway, respectively. The mean gestational age was in the range of 38.3–39.5 weeks in all exposure groups in both countries. The mean gestational ages tended to be higher in Norway compared to in the Czech Republic and higher in B-exposed than in M-exposed in both countries. When we studied neonates born at term (≥ 37 weeks of gestation), neonates exposed to M tended to have slightly lower mean values on all anthropometric parameters (weight, length and head circumference) in both countries compared to B exposure. In addition, in Norway, the proportion of SGA tended to be higher among M-exposed newborns. Very few pregnancies resulted in a miscarriage or stillbirth; no stillbirths were observed after B and BN exposure in both countries. The proportion with NAS was available only in Norway, where 54.7% of the M-exposed and 53.7% of the B-exposed newborns had NAS (Table 4). Twenty BN-exposed newborns in the Czech Republic did not have different neonatal outcomes than newborns exposed to M or B (Table 3).

Table 5 shows the results of linear and logistic regression analyses of neonatal outcomes comparing B with M in each country. In all analyses, except the SGA in the Czech Republic, the β and ORs were in the direction of more favourable outcomes in B-exposed newborns, but we observed no significant differences in neonatal outcomes in either the unadjusted or adjusted analyses between B- and M-exposed children in both countries.

| Socio-economic characteristics of women in opioid maintenance treatment during pregnancy in the Czech Republic. |
|---|---|---|---|---|---|
| Methadone (M) | Buprenorphine (B) | Buprenorphine with naloxone (BN) |
| **n** | **%** | **95% CI** | **n** | **%** | **95% CI** | **n** | **%** | **95% CI** |
| Total number | 158 | 154 | 21 |
| Age, years | | | | |
| ≤ 24 | 49 | 31.0 | 24.0–38.9 | 42 | 27.3 | 20.6–35.1 | 7 | 33.3 | 15.5–56.9 |
| 25–29 | 67 | 42.4 | 34.7–50.5 | 68 | 44.2 | 36.2–52.4 | 4 | 19.0 | 6.3–42.6 |
| 30–34 | 32 | 20.3 | 14.4–27.5 | 35 | 22.7 | 16.5–30.3 | 10 | 47.6 | 26.4–69.6 |
| ≥ 35 | 10 | 6.3 | 3.2–11.7 | 9 | 5.8 | 2.9–11.1 | 0 | 0.0 | 0.0–16.1 |
| Marital status | | | | |
| Not married | 126 | 79.7 | 72.5–85.6 | 123 | 79.9 | 72.5–85.7 | 17 | 81.0 | 57.4–93.7 |
| Married | 28 | 17.7 | 12.3–24.8 | 18 | 11.7 | 7.3–18.1 | 3 | 14.3 | 3.8–37.4 |
| Unknown | 4 | 2.5 | 0.8–6.8 | 13 | 8.4 | 4.8–14.3 | 1 | 4.8 | 0.3–25.9 |
| Education | | | | |
| Primary | 90 | 57.0 | 48.9–64.7 | 63 | 40.9 | 33.2–49.1 | 6 | 28.6 | 12.2–52.3 |
| Secondary | 59 | 37.3 | 29.9–45.4 | 84 | 54.5 | 46.3–62.5 | 11 | 52.4 | 30.3–73.6 |
| University | 0 | 0.0 | 0.0–2.3 | 1 | 0.6 | 0.3–4.1 | 3 | 14.3 | 3.8–37.4 |
| Unknown | 9 | 5.7 | 2.8–10.9 | 6 | 3.9 | 1.6–8.7 | 1 | 4.8 | 0.3–25.9 |
| Occupation | | | | |
| Unemployed | 143 | 90.5 | 84.6–94.4 | 117 | 76.0 | 68.3–82.3 | 14 | 66.7 | 43.1–84.5 |
| Employed | 11 | 7.0 | 3.7–12.4 | 12 | 7.8 | 4.3–13.5 | 2 | 9.5 | 1.7–31.8 |
| Unknown | 4 | 2.5 | 0.8–6.8 | 25 | 16.2 | 11.1–23.2 | 5 | 23.8 | 9.1–47.6 |
| Use of addictive substances during pregnancy | | | | |
| Alcohol | 8 | 5.1 | 2.4–10.1 | 9 | 5.8 | 2.9–11.1 | 0 | 0.0 | 0.0–16.1 |
| Smoking | 64 | 40.5 | 32.9–48.6 | 60 | 39.0 | 31.3–47.1 | 12 | 57.1 | 34.4–77.4 |
| Illicit drugs | 58 | 36.7 | 29.3–44.8 | 63 | 40.9 | 33.2–49.1 | 8 | 38.1 | 19.0–61.3 |
| Deliveries by multiplicity | | | | |
| Single | 152 | 96.2 | 91.6–98.5 | 152 | 98.7 | 94.9–99.8 | 20 | 95.2 | 74.1–99.8 |
| Twins and more | 6 | 3.8 | 1.6–8.5 | 2 | 1.3 | 0.2–5.1 | 1 | 4.8 | 0.3–25.9 |

CI = confidence interval.
In this observational study of two nation-wide cohorts, we investigated neonatal outcomes from prenatal exposure to M and B during pregnancy. Overall, the findings were very similar in the two countries. The neonatal outcomes in the B groups were better, albeit not significantly, compared to the M groups.

**DISCUSSION**

Table 2 Socio-economic characteristics of women in opioid maintenance treatment during pregnancy in Norway.

|                           | Methadone (M) | Buprenorphine (B) | Buprenorphine with naloxone (BN) |
|---------------------------|---------------|-------------------|----------------------------------|
|                           | n  | %   | 95% CI       | n  | %   | 95% CI       | n  | %   | 95% CI       |
| **Total number**          | 101|      |              | 99 |      |              | 35 |      |              |
| **Age, years**            |    |      |              |    |      |              |    |      |              |
| ≤ 24                      | 5  | 5.0 | 1.8–11.7     | 9  | 9.1 | 4.5–17.0     | 4  | 11.1 | 3.7–27.7     |
| 25–29                     | 26 | 25.7| 17.8–35.6    | 28 | 28.3| 19.9–38.4    | 16 | 45.7 | 29.2–63.1    |
| 30–34                     | 37 | 36.6| 27.4–46.9    | 42 | 42.4| 32.7–52.8    | 10 | 28.6 | 15.2–46.5    |
| ≥ 35                      | 33 | 32.7| 23.9–42.9    | 20 | 20.2| 13.1–29.7    | 5  | 14.3 | 5.4–31.0     |
| **Marital status**        |    |      |              |    |      |              |    |      |              |
| Not married               | 33 | 32.7| 23.9–42.8    | 41 | 41.4| 31.7–51.8    | 17 | 48.6 | 31.7–65.7    |
| Married/living with partner| 66 | 65.3| 55.2–74.4    | 58 | 58.6| 48.2–68.3    | 18 | 51.4 | 34.3–68.3    |
| Unknown                   | <4 |      |              | <4 |      |              | <4 |      |              |
| **Education**             |    |      |              |    |      |              |    |      |              |
| Primary                   | 84 | 83.2| 74.1–89.6    | 57 | 57.6| 47.2–67.3    | 27 | 77.1 | 59.5–89.0    |
| Secondary                 | 13 | 12.9| 7.3–21.4     | 39 | 39.4| 29.9–49.8    | 7  | 20.0 | 9.1–37.5     |
| University                | <4 |      |              | <4 |      |              | <4 |      |              |
| Unknown                   | <4 |      |              | <4 |      |              | <4 |      |              |
| **Smoking during pregnancy** |  |      |              |    |      |              |    |      |              |
| Yes                       | 64 | 63.4| 53.1–72.6    | 76 | 76.8| 67.0–84.4    | 21 | 60.0 | 42.2–75.7    |
| Unknown                   | 29 | 28.7| 20.4–38.7    | 12 | 12.1| 6.7–20.6     | 6  | 17.1 | 7.2–34.3     |
| **Deliveries by multiplicity** |  |      |              |    |      |              |    |      |              |
| Single                    | 99 | 98.0| 92.3–99.7    | 97 | 98.0| 92.2–99.7    | 33 | 94.3 | 79.5–99.0    |
| Twins and more            | <4 |      |              | <4 |      |              | <4 |      |              |

CI = confidence interval; < 4 denotes fewer than four individuals in the group. Exact numbers are not shown because of regulation from the Registries.

Table 3 Birth outcomes of children of women in opioid maintenance treatment during pregnancy in the Czech Republic; singleton pregnancy.

|                           | Methadone (M) | Buprenorphine (B) | Buprenorphine with naloxone (BN) |
|---------------------------|---------------|-------------------|----------------------------------|
|                           | n  | %   | 95% CI       | n  | %   | 95% CI       | n  | %   | 95% CI       |
| **Total number**          | 152|      |              | 152|      |              | 20 |      |              |
| **Gestational age** (weeks), mean (SD) | 38.5 (2.6) | 38.8 (2.7) | 38.5 (1.89) |
| **Birth weight** (g), mean (SD) | 3017 (476) | 3115 (453) | 2897 (450) |
| **Birth length** (cm), mean (SD) | 48.1 (2.4) | 48.6 (2.3) | 47.5 (2.3) |
| **Head circumference** (cm), mean (SD) | 33.8 (1.8) | 34.0 (1.5) | 33.7 (1.7) |
| **Caesarian section**      |    |      |              |    |      |              |    |      |              |
| Elective, n (%; CI)        | 5  | (3.4; 1.3–8.1) | 10 | (6.6; 3.4–12.1) | 3  | (15.0; 4.0–38.9) |
| **Acute**, n (%; CI)       | 17 | (11.2; 6.8–17.6) | 22 | (14.5; 9.5–21.3) | 1  | (5.0; 0.3–26.9) |
| **Stillbirth, n (%; CI)**  | 4  | (2.6; 0.8–7.0)  | 0  | (0.0; 0.0–2.4)   | 0  | (0.0; 0.0–16.8) |
| **Preterm birth, n (%; CI)** | 25 | (16.9; 11.4–24.1) | 25 | (16.4; 11.1–23.5) | 4  | (20.0; 6.6–44.3) |
| **Small for gestational age** (SGA), n (%; CI) | 19 | (12.8; 8.1–19.6) | 21 | (13.8; 8.9–20.6) | 3  | (15.0; 4.0–38.9) |
| **Apgar score < 7 at 1 min** |    |      |              |    |      |              |    |      |              |
| Yes, n (%; CI)             | 13 | (8.8; 5.0–14.9) | 13 | (8.6; 4.8–14.5) | 2  | (10.0; 1.8–33.1) |
| No, n (%; CI)              | 135| (91.2; 85.1–95.0) | 139| (91.4; 85.5–95.2) | 18 | (90.0; 66.9–98.2) |
| **Apgar score < 7 at 5 min** |    |      |              |    |      |              |    |      |              |
| Yes, n (%; CI)             | 5  | (3.4; 1.3–8.1)  | 2  | (1.3; 0.2–5.2)   | 0  | (0.0; 0.0–16.8) |
| No, n (%; CI)              | 143| (96.6; 91.9–98.7) | 150| (98.7; 94.8–99.8) | 20 | (100; 83.2–100) |

Singleton and live births; *singleton births with gestational age ≥ 37 weeks. CI = confidence interval; SD = standard deviation.
Table 4  Birth outcomes of children of women in opioid maintenance treatment during pregnancy in Norway; singleton pregnancy.

|                                | Methadone (M) | Buprenorphine (B) | Buprenorphine with naloxone (BN) |
|--------------------------------|---------------|-------------------|----------------------------------|
| Total number                    | 99            | 97                | 33                               |
| Gestational ageb (weeks), mean (SD) | 38.9 (1.9) | 39.2 (2.4)        | 39.5 (1.7)                       |
| Birth weighta (g), mean (SD)     | 3268 (603)    | 3333 (437)        | 3235 (393)                       |
| Birth lengtha (cm), mean (SD)    | 48.7 (3.0)    | 49.3 (2.0)        | 49.0 (1.8)                       |
| Head circumferencec (cm), mean (SD) | 34.4 (1.5)   | 34.7 (1.6)        | 34.7 (1.2)                       |
| Abortion induced                 | < 4           | (0; 0.0–0.3)      | < 4                              |
| Miscarriage                      | 0 (0.0; 0.3–3.7) | 97 (100; 96.3–100) | 32 (97.0; 82.5–99.8)             |
| Caesarian sectionb               | 10 (10.3; 5.3–18.6) | 12 (12.4; 6.8–21.0) | < 4                              |
| Preterm birthb, n (%)            | 9 (9.3; 4.6–17.3) | 5 (5.2; 1.9–12.2) | < 4                              |
| Small for gestational ageb (SGA), n (%) | 10 (10.3; 5.3–18.6) | 5 (5.2; 1.9–12.2) | 0 (0.0; 0.0–10.6)                |
| Apgar scoreb < 7 at 1 min        | 7 (7.4; 3.3–15.2) | 5 (5.2; 2.0–12.5) | < 4                              |
| Apgar scoreb < 7 at 5 min        | 87 (92.6; 84.8–96.7) | 89 (94.7; 87.5–98.0) | 31 (96.9; 82.0–99.8)             |
| Neonatal abstinence syndromeb    | 52 (54.7; 44.2–64.9) | 51 (53.7; 43.2–63.9) | 17 (53.1; 35.0–70.5)             |

CI = confidence interval; SD = standard deviation; < 4 denotes fewer than four individuals in the group. Exact numbers are not shown because of regulation from the Registries. *Singleton births with gestational age ≥ 37 weeks; +singleton and live births.

A systematic review and meta-analysis concluded that B treatment, compared to M, during pregnancy seemed to have a lower risk of unfavourable birth outcomes, such as lower anthropometric data in the unadjusted analyses [12]. In our study, the B-exposed neonates born at term had higher birth weight (about 50–100 g) than the M-exposed group, but these differences were not significant. Apart from the statistical significance, the clinical perspective is also important. To put these observed differences into context, tobacco smoking reduces birth weight by approximately 200 g—a difference considered clinically relevant [35].

Some earlier studies showed a lower NAS prevalence after exposure to B compared to M [36,37]. We found no difference in prevalence of NAS in the M and B groups in the Norwegian sample. This is in line with findings in an RCT performed by Jones et al. [38], who reported no significant difference in prevalence of NAS in B and M groups in the adjusted analysis, although B-exposed neonates required less intensive NAS treatment than M-exposed newborns. A systematic review and a meta-analysis, where the unadjusted results from Jones et al. were also included, showed differences between M and B in unadjusted NAS treatment risk. However, the authors point out that some of these differences may be due to confounding by indication, and when Jones et al. performed an adjusted analysis the differences disappeared [11]. Indeed, only few studies comparing the safety of B versus M on the neonate adjust for confounding [39].

A small group of women in the Czech sample received BN throughout pregnancy. The findings suggest that the neonatal outcomes in BN-exposed newborns were not different from those who were exposed to B or M. However, the confidence intervals in the BN group were wide because of the low number of exposed newborns. Our findings are in line with other studies that have looked at the safety of BN [16], suggesting that it may be a safe treatment alternative. Note that all existing studies on safety of BN use very small study samples.

Methodological considerations

As almost all women in OMT are registered in the national registries, our study had two national cohorts and selection bias is less of a problem in the current study compared to previous studies. Further, the size of the sample is a strength of our study [19], as the majority of previous
studies on neonatal outcomes included small samples. The two cohorts represent different parts of Europe and are heterogeneous, which may increase the generalizability of the results.

Using information from the registries reduces the risk of recall bias, and studies based on data from health registries can identify and follow more women in OMT over time than can feasibly be included in clinical samples. There is an indication that some previous studies may have been affected by selection bias. For example, Welle-Strand and colleagues [27] based their study on a Norwegian clinical sample from 1996 to 2009, while our register study used data starting from 2004. Approximately two-thirds of the women from the clinical study were also included in our study. When comparing differences after M and B exposure in birth weights, not restricted to term pregnancies in any of the studies, these differed notably. In the study by Welle-Strand and colleagues the difference was 310 g. In contrast, our study showed a difference of only 53 g (not shown in the table, where we show only the birth weight restricted to term pregnancies). Including an almost complete national sample of OMT-exposed newborns gave a more precise mean value of birth weight than did the clinical sample. The comparison between these studies shows how selection may give rise to imprecise estimates.

Another possible explanation for the observed difference in birth weight between the clinical study by Welle-Strand and our registry study is that confounding by indication is more of a problem in the clinical study. In Norway, the criteria for OMT used to be very strict; only the most severely addicted women qualified for OMT. Since then, the criteria have become less strict, and B is now the recommended treatment for pregnant women who are opioid-dependent. A great proportion of the women included in the first years of the Welle-Strand study were probably

### Table 5

Linear† and binary logistic regression§ comparing buprenorphine to methadone during pregnancy in the Czech Republic and in Norway.

|                      | Czech Republic |                      | Norway |                      |
|----------------------|----------------|----------------------|--------|----------------------|
|                      | buprenorphine versus methadone (ref.) | buprenorphine versus methadone (ref.) |
| **Gestational age**  |                |                      |        |                      |
| Unadjusted           | 0.16           | -0.44 to 0.77        | 0.28   | -0.33 to 0.90        |
| Adjusted             | 0.05           | -0.68 to 0.59        | 0.48   | -0.29 to 1.25        |
| **Birth weight**     |                |                      |        |                      |
| Unadjusted           | 98.4           | -17.2 to 214.0       | 64.9   | -91.0 to 220.8       |
| Adjusted             | 111.6          | -10.5 to 233.6       | 83.1   | -100.8 to 267.0      |
| **Birth length**     |                |                      |        |                      |
| Unadjusted           | 0.47           | -0.12 to 1.06        | 0.56   | -0.22 to 1.33        |
| Adjusted             | 0.45           | -0.17 to 1.08        | 0.47   | -0.35 to 1.29        |
| **Head circumference**|               |                      |        |                      |
| Unadjusted           | 0.19           | -0.31 to 0.69        | 0.36   | -0.11 to 0.82        |
| Adjusted             | 0.12           | -0.41 to 0.65        | 0.57   | -0.04 to 1.18        |
| **OR**               |                |                      |        |                      |
| Preterm birth        |                |                      |        |                      |
| Unadjusted           | 0.97           | 0.53 to 1.78         | 0.53   | 0.17 to 1.65         |
| Adjusted             | 0.92           | 0.48 to 1.74         | 0.73   | 0.16 to 3.36         |
| SGA                   |                |                      |        |                      |
| Unadjusted           | 1.09           | 0.56 to 2.12         | 0.47   | 0.16 to 1.44         |
| Adjusted             | 1.07           | 0.52 to 2.21         | 0.83   | 0.22 to 3.20         |
| Apgar score < 7 at 5 min |            | 0.38           | 0.07 to 2.00 | NA  | NA |
| Adjusted             | 0.20           | 0.02 to 2.13         | NA     | NA                   |
| Neonatal abstinence syndrome |       | Unadjusted           | 0.96   | 0.54 to 1.70         |
| Adjusted             | NA             | NA                   | 0.94   | 0.46 to 1.92         |

†β (regression coefficients) from linear regression for gestational age, birth weight, length and head circumference; §odds ratios (ORs) from binary logistic regression of having child birth small for gestational age (SGA), premature birth and Apgar score < 7, neonatal abstinence syndrome (Norway); §singleton and live births; *adjusted for age, marital status, education, smoking; §singleton births with gestational age ≥ 37 weeks. Data were not available (NA) for the Czech Republic sample; there were fewer than four individuals in the Norwegian sample.
more severely addicted than many women in our study, as they qualified for the strict OMT regimen, and probably received M because this was the recommended drug. This might have induced confounding by indication; newborns exposed to M probably had more severely addicted mothers than newborns exposed to B.

Because M is a full opioid agonist, pregnant women who receive M under today’s recommendations are typically heavier drug users than women treated with the partial agonist B. In the Czech Republic, opioid-dependent women treated with B are probably also in a better socio-economic situation compared to women treated with M, as they must pay a substantial amount of money for B and M is free of charge. Adjusting for variables representing socio-economic status tended to decrease the estimates very slightly in the Czech Republic. M women in Norway are probably also heavier drug users than B women. However, in the Norwegian sample a higher proportion of B women smoked and were single compared to M women. These factors may contribute to the slight increase in the estimates after adjustment. A limitation with using registry data is that the registries include fewer confounding factors than do clinical studies. Some important information is under-reported, or reported in insufficient format in the registries, e.g. use of alcohol, tobacco and illicit drugs in the Czech sample [29] and smoking in the Norwegian sample, or missing, e.g. use of alcohol and illicit drugs in Norwegian sample. Further, information on nutrition, infections during pregnancy and the women’s body mass index (BMI) is lacking. Missing values in any of the maternal background variables reduce the sample size in the multivariate regression analyses and may introduce selection bias. In this study, this was relevant for the smoking variable.

Only information concerning prescription drugs dispensed to out-patients in Norway is included in NorPD. Thus, pregnant women receiving OMT in residential treatment were not included in our OMT groups. We assume this is true for a limited number of cases [26].

Multiple pregnancies have an effect on several neonatal outcomes. In our study, therefore, only singleton pregnancies were included in the analysis of the neonatal outcomes.

Even though our samples of pregnant women in OMT are among the largest to date they are still relatively small, resulting in difficulty when studying rare outcomes such as stillbirths and miscarriages. There was a tendency in many of the outcomes in both countries for B to perform better than M, but the differences were not statistically significant. If these tendencies are real, larger sample sizes are needed.

**CONCLUSION**

Although B exposure resulted in more favourable neonatal outcomes compared to M, the differences were not significant and the tendencies observed might possibly still be attributed to residual confounding.

**Declaration of interests**

None.

**Acknowledgements**

This study was supported by the Ministry of Health of the Czech Republic, grant no. 16-28157A, the Grant Agency of the Czech Republic grant no. 14-07822S and the Charles University institutional support no. Progres Q06/LF1. The Scandinavian cohort study has received grants from the Norwegian Research Council, grant no. 240197/H10.

**References**

1. World Health Organization (WHO). Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva: WHO; 2014.

2. Klaman S. L., Isaacs K., Leopold A., Perpich J., Hayashi S., Vender J. et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med 2017; 11: 178–90.

3. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. J. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assess (Winchester, UK) 2007; 11: 1–171; iii–iv.

4. Věstník MZ ČR částka 3/2008—Standard substituční léčby [journal of the Ministry of Health of the Czech Republic no. 3/2008—Standard of substitution treatment]. Prague: Ministerstvo zdravotnictví ČR [Ministry of Health of the Czech Republic]; 2008.

5. Bakstad B., Welle-Strand G. Nasjonal retningslinje for gravid tåke i legemiddelassistent rehabilitering (LAR) og oppfølgings av familien fra till barnet når skolealdar [National Guidelines For Pregnant Women In Opioid Maintenence Treatment (OMT) and Follow-Up Of Their Families Until the Children Reach School Age]. Oslo, Norway: Norwegian Directorate of Health; 2011.

6. Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEIGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.

7. Finnegan L. P., Reeser D. S., Connaughton J. F. Jr. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend 1977; 2: 131–40.

8. Kandall S. R., Albin S., Lowinson J., Berke B., Eidelman A. L., Gartner L. M. Differential effects of maternal heroin and methadone use on birthweight. Pediatr Acta 1976; 58: 681–5.

9. Finnegan L. P., Connaughton J. F., Einrich J. P., Wieland W. F. Comprehensive care of the pregnant addict and its effect on maternal and infant outcome. Contemp Drug Prod 1972; 1: 795–809.

10. Walsh S. L., Preston K. L., Bigelow G. E., Stitzer M. L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361–72.
11. Brogly S. B., Saia K. A., Walley A. Y., Du H. M., Sebastiani P. Pre- and neonatal outcomes: systematic review and meta-analysis. *Am J Epidemiol* 2014; 180: 686.

12. Zedler B. K., Mann A. L., Kim M. M., Amick H. R., Joyce A. R., Murrelle E. L. et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. *Addiction* 2016; 111: 2115–28.

13. Bakstad B., Sarli M., Welle-Strand G. K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. *Eur Addict Res* 2009; 15: 128–34.

14. Debelak K., Morrone W. R., O’Grady K. E., Jones H. E. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. *Am J Addict* 2013; 22: 252–4.

15. Fischer G., Ortmann R., Rohrmeister K., Jagsch R., Baeuvert A., Langer M. et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. *Addiction* 2006; 101: 275–81.

16. Lund I. O., Fischer G., Welle-Strand G. K., O’Grady K. E., Debelak K., Morrone W. R. et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. *Subst Abuse* 2013; 7: 61–74.

17. Peles E., Sason A., Schreiber S., Adebosan M. Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: a national contingency management approach trial. *Am J Addict* 2017; 26: 167–75.

18. Meyer M., Phillips J. Caring for pregnant opioid abusers in Vermont: a potential model for non-urban areas. *Prev Med* 2015; 80: 18–22.

19. Gabrhelik R., Nechanská B., Mravčík V., Skurtveit S., Lund I. O., Handal M. A unique opportunity to study short and long term consequences in children prenatally exposed to illicit drugs and opioid maintenance treatment using Czech and Scandinavian registers. *Cen Eur J Public Health* 2016; 24: 248–51.

20. Popov P. Metadonová substituční léčba v České republice [Methadone substitution treatment in the Czech Republic]. *Addiktologie* 2002; 2: 25–31.

21. Mravčík V., Pešek R., Skalupová K., Orliková B., Škrkulantová E., Šustášová L. et al. Annual Report on the Czech Republic 2008 Drug Situation. Prague: Office of the Government of the Czech Republic, National Monitoring Centre For Drugs And Drug Addiction; 2009.

22. Zůbranský T., Češny L., Gajdošová H., Korčišová B., Kuda A., Mirovszky M. et al. Výroční zpráva o stavu a vývoji ve věcech drog v České republice za rok 2001 [Annual Report of The Czech Republic 2001 Drug Situation]. Prague: Uřad vlády ČR; 2002.

23. Nechanská B. Událost v Národním registru uživatelů lékárenských indikovaných substitučních látek—rok 2012. Aktuální informace č. 01/2013 [Data in the National Register of Users of Medically Indicated Substitution Substances—2012. Current Information no. 01/2013]. Prague: ÚZIS ČR; 2013.

24. Mravčík V., Orliková B. Překrývá klientů mezí jednotlivými nízkoprahovými programy a zneužívání buprenorfinu v Praze [The overlap of clients among low-threshold programmes in Prague and the assessment of current drug situation in Prague with emphasis on buprenorphine misuse]. *Adiktologie* 2007; 7: 13–20.

25. Norwegian Directorate of Public Health (MHuSA). National Guidelines for Opioid Maintenance Treatment of opioid Depend- [Nasjonal retningslinje for legemidelsassistert rehabilitering ved opioidavhengighet]. Oslo, Norway: Norwegian Institute of Public Health; 2010.

26. Lund I. O., Skurtveit S., Engeland A., Furu K., Ravndal E., Handal M. Prescription drug use among pregnant women in opioid maintenance treatment. *Addiction* 2013; 108: 367–76.

27. Welle-Strand G. K., Skurtveit S., Jones H. E., Waal H., Bakstad B., Bjärko L. et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. *Drug Alcohol Depend* 2013; 127: 200–6.

28. Lov 1999, nr 61. Sosialjustisjonstelenlov § 6-2a.Tilbakeholdelse av gravide rusmisbrukere [Social Services Act § 6-2a Retention of substance dependent pregnant women in institutions]. Norway: 2010.

29. Nechanská B., Mravčík V., Sopko B., Velebil P. Rodičky užívající alkohol, tabák a nelegální drogy [Pregnant women and mothers using alcohol, tobacco and illegal drugs]. *Česká Gynekol* 2012; 77: 457–69.

30. Nechanská B., Mravčík V., Popov P. Máme se bát národního registru léčby uživatelů drog? [Should we worry about the national registry of drug treatment?]. *Česká Slov Psychiatr* 2015; 111: 117–8.

31. Nechanská B., Mravčík V., Popov P. Národní registr léčby uživatelů drog [The National Register of Drug Users in Treatment]. *Addiktologie* 2014; 14: 364–5.

32. World Health Organization (WHO). WHO Collaborating Centre for Drug Statistics Methodology. *ATC Classification Index with DDDs 2010*. Oslo, Norway: Norwegian Institute of Public Health; 2010.

33. Marsal K., Persson P. H., Larsen T., Lilja H., Selbing A., Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. *Acta Pediatri* 1996; 85: 843–8.

34. Volset S. E. Confidence intervals for a binomial proportion. *Stat Med* 1993; 12: 809–24.

35. Haug K., Irgens L. M., Skjerven R., Markestad T., Baste V., Schreuder P. Maternal smoking and birthweight: effect modification of period, maternal age and paternal smoking. *Acta Obstet Gynecol Scand* 2000; 79: 485–9.

36. Lacroix I., Berrebi A., Garipuy D., Schmitt L., Hammou Y., Chaumel L. et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. *Eur J Clin Pharmacol* 2011; 67: 103–9.

37. Norgaard M., Nielsson M. S., Heide-Jorgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study. *Subst Abuse* 2015; 9: 5–11.

38. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med* 2010; 363: 2320–31.

39. Brogly S. B., Hahn K. A., Díaz S. H., Werler M. Confounding of the comparative safety of prenatal opioid agonist therapy. *Addict Res Ther* 2015; 6: 252.